PA Medical News about etanercept ankylosing spondylitis;uveitis

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Use of Antiemetic Agents in Acute Gastroenteritis

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials
Annals of Rheumatic Diseases, 06/09/09

Sieper J et al. – Study demonstrates that in ankylosing spondylitis (AS) patients, rates of uveitis events with etanercept were lower than with placebo in placebo-controlled trials and similar to sulfasalazine in an active-comparator trial.

Methods

Aim was to assess uveitis (including iritis and iridocyclitis) incidence from clinical trials of etanercept in AS pts
4 placebo-controlled; 1 active-controlled; and 3 open-label trials were examined for reports of uveitis
Between-group differences in the uveitis rates were calculated for the double-blind, active-controlled, and long-term studies

Results

In placebo-controlled trials, the uveitis rate per 100 subject yrs for etanercept was lower vs placebo
In the active comparator trial, rates for etanercept and sulphasalazine were similar
Long-term rate for etanercept, estimated from both placebo-controlled and open-label extension studies was 12.0